Both nonionic iodinated contrast medium and gadolinium-based contrast medium rarely cause allergic-like reactions.
Allergic-like reactions to both nonionic iodinated contrast medium (ICM) and gadolinium-based contrast medium (GBCM) are extremely rare and when events do occur, they present as mild acute reactions without significant clinical consequences, according to a study published in the American Journal of Roentgenology.
Researchers from Northwestern University-Feinberg School of Medicine in Chicago, Ill., sought to determine the incidence rate and clinical characteristics of allergic-like reactions that occurred over a five-year period among patients who received ICM and GBCM but had not received allergy preparations.
A total of 302,858 contrast injections were evaluated, 155,234 ICM and 147,624 GBCM. Of these, 1,006 (752 ICM and 254 GBCM) resulted in acute allergic-like contrast reactions. The overall rate of reaction to ICM was 0.48 percent and the overall rate of reaction to GBCM was 0.17 percent. A total of 19,237 patients received at least one ICM injection and one GBCM injection, with a total of 56,310 injections (19,237 initial injections and 37,073 subsequent injections).
Nine patients had reactions to both ICM and GBCM with the primary reaction rate of 9 out of 19,237 and the secondary reaction rate of 9 out of 37,073. None of the patients required medication for the treatment of the secondary reaction as all secondary reactions in patients who had a reaction to both ICM and GBCM were mild.
The researchers concluded that allergic-like reactions to both nonionic ICM and GBCM were extremely rare and when they did occur, they were mild acute reactions without significant clinical consequences despite the fact that an allergy preparation was not administered.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.